News

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Notice of Investment Agreement with AN Venture Partners

Regarding the Acquisition of Manufacturing and Marketing Approval for the New Siderophore Cephalosporin Antibiotic Fetroja^Ⓡ(cefiderocol) Intravenous Infusion 1g vial in Japan

Stream-I, Inc. Launches New Home Palliative Care Support Service 'Home Care Base'

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Transcript of the FY2023 2Q Financial Results Conference

Notice of Investment with J.P. Morgan Asset Management’s Life Sciences Private Capital

2023 SHIONOGI Integrated Report have been issued

Establishment of a Joint Venture Company with Apnimed for Solving Challenges in Sleep Disorders

Announcement of the Sales Partnership Agreement in Japan between Shionogi and Mochida regarding Insomnia Treatment Drug Daridorexant

Presentation Materials for FY2023 2Q financial results

Notice Regarding Interim Dividend for the Fiscal Year Ending March 31, 2023

Financial Results and Supplement and Press Conference for FY2023 2Q

Notice Regarding Results of an Early Retirement Program

Presentation Materilals and Transcript of Sustainability Meeting

Notice of alert regarding impersonation accounts

Transcript of HIV follow-up meeting

Research Findings and Initiatives on Malaria, One of the Three Major Infectious Diseases, Featured in Nature Magazine's 'Nature Outlook: Malaria' Edition.

IDWeek 2023: Shionogi Presents New Real-World Evidence Demonstrating Effectiveness of Earlier Treatment with Fetroja®(cefiderocol) in Appropriate Patients

Shionogi Presents New Ensitrelvir COVID-19 Data Supporting Effectiveness in Real-World and Clinical Settings at IDWeek 2023

Announcement regarding “SHIONOGI Infectious Disease Weeks”
~To think together about tomorrow's infectious diseases and fight together with you~

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Zatolmilast, an Investigational Treatment for Fragile X Syndrome, Receives Rare Pediatric Disease Designation from the U.S. FDA

Transcript of the ESWI 2023 follow-up meeting

Regarding the Adoption of Public Offering for “the Project that Establish Biopharmaceutical Manufacturing Bases to Strengthen Vaccine Production Structure” Led by the Ministry of Economy, Trade and Industry
- Establishing domestic vaccine manufacturing for future pandemics -

Presentation Material of ESWI 2023 Follow Up Meeting

Shionogi Presents New Ensitrelvir Clinical and Real-World Data Reinforcing Potential Across COVID-19 Populations at ESWI 2023

Critical agreement paves way for new model to accelerate access to important antibiotics for serious bacterial infections

IDWeek 2023: Shionogi and Qpex Biopharma, Inc.
Continue Longstanding Commitment to Addressing Unmet Needs in Infectious Disease

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Notice Regarding the Inclusion of Nasal Vaccine Research and Development for Influenza Virus and SARS-COV2 / New Modality Research and Development Project by AMED

Shionogi Announces Corporate Reorganization and Personnel Reassignment

Flomox® Fine Granules for children oral cephem antibiotic agent Launched in China

Transcript of the First Quarter of FY2023 Financial Results Conference

Toward the Establishment of a Supply-Chain System to Secure a Stable Domestic Supply of Antibacterial Drugs
－Certification of “Plan for Stable Supply of Antibacterial Substances” by Ministry of Health, Labour and Welfare－

Notice Regarding Acquisition of Own Shares and Cancellation of Treasury Shares (Acquisition of own shares pursuant to the provisions of Article 165, paragraph 2 of the Companies Act and cancellation of treasury stocks pursuant to the provisions of Article 178 of the Companies Act)

Financial Results and supplement for FY2023 1Q

Presentation Materials for FY2023 1Q financial results

Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan

Notice Regarding Implementation of an Early Retirement Program

Shionogi Filed for a Supplemental New Drug Application of XOFLUZA® (Baloxavir Marboxil) in Taiwan for Pediatrics Aged 5 to Under 12 for the Treatment and Prevention of Influenza Infection

Eddingpharm Announces Approval of Mulpleta® (Lusutrombopag) in China

Initiation of a Phase 3 Clinical Trial in Japanese Pediatric Patients of Ensitrelvir for COVID-19

Seven manufacturers sign sublicence agreements with the Medicines Patent Pool to produce generic versions of Shionogi's COVID-19 oral antiviral ensitrelvir to increase access in low- and middle-income countries.

Shionogi Further Extends Infectious Disease Innovation Platform with Planned Acquisition of Qpex Biopharma, Inc.

Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan

Update on Antigen Design for Universal Sarbecovirus Vaccine by Shionogi and KOTAI

Shionogi to Announces Appointment of Corporate Officers

Shionogi Enrolls the First Participant in Japan in its Global Phase 3 Trial of Ensitrelvir for the Prevention of Symptomatic SARS-CoV-2 Infection

Transcript of Medium-Term Business Plan STS2030 Revision

Presentation Materials for Revision of the Medium-Term Business Plan STS2030

Revision of the Medium-Term Business Plan STS2030

Launch of the Third Phase for the Mother to Mother SHIONOGI Project New Activities to Support Maternal and Child Health in Kenya and Ghana

Contribution to the Global Health Innovative Technology Fund (GHIT Fund) for the Third Phase

Orphan Drug Designation for Redasemtide for Dystrophic Epidermolysis Bullosa

Shionogi Expands its COVID-19 Product Portfolio by Initiating a Phase 1 Clinical Trial in Japan for a Second COVID-19 Antiviral

Transcript of FY2022 Financial Results

Presentation Materials for FY2022 financial results

Financial Results and supplement for FY2022

Notice Regarding Announcement of Financial Results for the Fiscal Year Ending March 31, 2023 (May 10)

Shionogi to Announce Personnel Reassignment

Notice of Revisions to Dividend Forecasts (Dividend Increase)

Position and Policy Regarding Reduction of the Investment Unit

ECCMID 2023: Shionogi Announces Real-World Evidence Demonstrating the Efficacy of Fetcroja® / Fetroja® (cefiderocol) Against Some of the Most Difficult-to-Treat Gram-Negative Bacterial Pathogens

Shionogi Certified as the First Eco-First Company in the Pharmaceutical Industry of Environmentally Advanced Company

Shionogi filed for Emergency Use Authorization of Ensitrelvir Fumaric Acid in Taiwan, for the Treatment of COVID-19

Initiation of a Global Late Phase 2 Clinical Trial of the Regeneration Inducing Medicine® Redasemtide in Patients with Acute Ischemic Stroke

ECCMID 2023: Shionogi to Present Data Showing COVID-19 Symptom Recurrence is Not Associated with Ensitrelvir Treatment

Additional Data to be Presented Showing Significantly Faster Time to Negative Viral Titer (Culture) Compared to Placebo

Shionogi Receives U.S. FDA Fast Track Designation for Ensitrelvir Fumaric Acid, an Investigational Oral Antiviral for COVID-19

Transcript for HIV Business Meeting

Presentation material for HIV Business Meeting

Notice of a Limited Partner Investment Agreement with LSP Dementia Fund

SHIONOGI to Announce Executive Appointments

Shionogi has been recognized as one of the highest-ranking companies on the Supplier Engagement Rating (Climate Change) by CDP

Shionogi to Announce Personnel Reassignment

Notice of Collaboration Agreement for the Discovery and Development of Novel Malaria Drugs with Nagasaki University and MMV, Supported by the GHIT Fund

Shionogi Wins Second Prize in NIKKEI Integrated Report Award 2022

Shionogi has been Selected as One of the Excellent Integrated Reports by the GPIF's Domestic Equity Managers for the Third Consecutive Year

Shionogi to Announce Personnel Reassignment

Presentation Material and Transcript of CROI 2023 Follow Up Meeting

Shionogi Supports Victims of the Earthquake in Turkey and Syria

Shionogi Presents Pivotal Ensitrelvir Fumaric Acid Phase 3 Data and Exploratory Long COVID Data at CROI

Forming of a Joint Venture with Accenture Co., Ltd. Accompanied by a Share Transfer of Shionogi Business Partner Co., Ltd.

Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program

Notice Regarding Completion of Cancellation of Treasury Shares

Transcript of FY2022 Q3 Financial Results

Presentation Materials for FY2022 2Q financial results

Financial Results and supplement for FY2022 2Q

Notice of Revisions to Earnings Forecasts for the fiscal year ending March 31, 2023

Shionogi to Announce Personnel Reassignment

Initiation of a Phase1/2/3 Clinical Trial (Part 2) and Phase 3 Additional Dose Clinical Trial in Japanese Pediatric Subjects of the COVID-19 Recombinant Protein-based Vaccine, S-268019

New Drug Application of Ensitrelvir Fumaric Acid, a Therapeutic Drug for COVID-19 Accepted for Review in South Korea